Quantify is actively engaging in retrospective research in the field of chronic liver disease, and Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH), in particular. Quantify has initiated a large retrospective study, HEalth outcomes and Risk Assessment in chronic Liver Disease (HERALD), together with Karolinska University Hospital and Karolinska Institutet, Department of Medicine, Huddinge.
CHRONIC LIVER DISEASE
Chronic Liver Disease is a disease process of the liver that involves a process of progressive destruction and regeneration of the functional tissue of the liver, leading to fibrosis and cirrhosis. Causes of CLD can be viral (e.g. hepatitis C), toxic (e.g. alcohol), Metabolic (e.g. NAFLD/NASH), or autoimmune (e.g. autoimmune hepatitis, primary biliary cholangitis). In 2017, there were 2.14 million liver-related deaths globally, predominantly due to liver-cancer and cirrhosis. Viral hepatitis remains the most common cause of liver deaths, and NAFLD is the most rapidly growing contributor to liver mortality and morbidity.
NAFLD is the most common metabolic CLD, which occurs when fat accumulates in the liver due to other causes than long-term excessive alcohol consumption . There are two types of NAFLD; simple fatty liver (also called non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH). Individuals with NASH are also at greater risk of type 2 diabetes and cardiovascular disease, and vice versa.